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Variation in major histocompatibility complex genes on chromosome 6p21.3, specifically the human leuko-
cyte antigen HLA-DR2 or DRB1*1501-DQB1*0602 extended haplotype, confers risk for multiple sclerosis
(MS). Previous studies of DRB1 variation and both MS susceptibility and phenotypic expression have
lacked statistical power to detect modest genotypic influences, and have demonstrated conflicting results.
Results derived from analyses of 1339 MS families indicate DRB1 variation influences MS susceptibility in
a complex manner. DRB1*15 was strongly associated in families (P 5 7.8 3 10231), and a dominant
DRB1*15 dose effect was confirmed (OR 5 7.5, 95% CI 5 4.4–13.0, P<0.0001). A modest dose effect was
also detected for DRB1*03; however, in contrast to DRB1*15, this risk was recessive (OR 5 1.8,
95% CI 5 1.1–2.9, P50.03). Strong evidence for under-transmission of DRB1*14 (P 5 5.7 3 1026) even after
accounting for DRB1*15 (P 5 0.03) was present, confirming a protective effect. In addition, a high
risk DRB1*15 genotype bearing DRB1*08 was identified (OR 5 7.7, 95% CI 5 4.1–14.4, P<0.0001),
providing additional evidence for trans DRB1 allelic interactions in MS. Further, a significant DRB1*15
association observed in primary progressive MS families (P 5 0.0004), similar to relapsing-remitting
MS families, suggests that DRB1-related mechanisms are contributing to both phenotypes.
In contrast, results obtained from 2201 MS cases argue convincingly that DRB1*15
genotypes do not modulate age of onset, or significantly influence disease severity measured
using expanded disease disability score and disease duration. These results contribute
substantially to our understanding of the DRB1 locus and MS, and underscore the importance of using
large sample sizes to detect modest genetic effects, particularly in studies of genotype–phenotype
relationships.
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INTRODUCTION
Multiple sclerosis (MS) is a chronic inflammatory disorder of
the central nervous system (CNS) characterized by demyelina-
tion, astrogliosis, varying degrees of axonal pathology and a
relapsing or progressive course (1). Although aetiologic mech-
anisms are uncertain, MS risk is determined by an underlying
complex genetic component likely acting in concert with
undefined environmental exposures. Genetic susceptibility to
MS is associated with the human leukocyte antigen HLA
region located on the short arm of chromosome 6. There are
two major classes of HLA genes. The telomeric stretch of
the locus contains the class I genes, whereas the centromere
proximal region encodes HLA-class II genes. HLA class I
and class II encoded molecules are highly polymorphic cell
surface glycoproteins playing a fundamental role in self/
non-self immune recognition. The association of MS with
HLA class II genes, specifically the HLA-DR2 or DRB115
haplotype (DQB10602, DQA10102, DRB11501,
DRB50101), has been a consistent finding across nearly all
populations (2). The exact mechanism(s) by which the
DRB115 haplotype influences susceptibility to MS remain
undefined, but are likely related to the physiological function
of HLA molecules in immune responses, including antigen
binding and presentation, and T cell repertoire determination
by negative selection of high-avidity autoreactive T cells
within the embryonic thymic microenvironment (3,4).
In multi-case MS families, linkage and association to the
HLA-DRB1/DQB1 locus have also been unambiguously man-
ifested (5–7), but remarkably, all linkage information and evi-
dence for association have been derived from families in
which DRB115 was present in at least one nuclear member
(7,8). There are no reports of statistically significant evidence
for linkage in DRB115 negative families, although some
researchers have observed modest linkage (9), underscoring
the complex genetic nature of this disease. The debate con-
cerning the role of non-HLA class II genes mapping to this
region continues, with some data suggesting that additional
susceptibility genes lie within the central class III (10,11)
and/or telomeric to the class I HLA regions (12–15).
However, a recent high-density SNP study covering the
region assigns the entire association signal to the HLA-class
II region (16), and DRB1 itself remains the strongest candidate
for the disease-associated locus.
Recent studies of the HLA class II MS association have
refined the location of the primary effect to DRB115
(17,18) and detected an unexpected DR2 (DRB115) allele
dose effect on susceptibility (19). Further, strong evidence
for DRB1 allelic and genotypic heterogeneity (13,17,20,21)
has been reported. Together, these data are helping to refine
the conceptual model of MS pathogenesis and suggest the
possibility that complex trans DRB1 allelic interactions may
determine the balance between susceptibility and resistance.
Recent reports of disease protective DRB1 alleles by
Dyment et al. require confirmation (21), and additional ques-
tions about DRB1 variation and clinical manifestations also
persist; for example, HLA-DRB115 has been associated
with an earlier age of disease onset, female gender, severe,
relapsing-remitting (RRMS) and mild MS courses (19,22–
24), or has shown a very minor or no influence on disease
course (25–27). Complete resolution of these important
issues is crucial to fully understand the role of DRB1 in
disease pathogenesis. In this study, one of the largest familial
MS datasets, to date, was assembled, including 1339 families
and a total of 2294 cases, to comprehensively study the
HLA-DRB1 locus in MS. The results provide strong evidence
for complex genotypic DRB1 patterns associated with suscep-
tibility, but not age of onset or disease progression, and
demonstrate the need to study large and well-characterized
datasets for complex phenotypes even in the evaluation of
primary genetic determinants.
RESULTS
To better understand the role of HLA-DRB1 variation in MS
and, in particular, the risk and phenotype associated with
DRB115 genotypes, we comprehensively analyzed the
DRB1 locus in 1339 well-characterized MS families (total
4669 individuals: 1571 MS cases and 3098 unaffected
family members). Around 85% of families were of northern
European origin residing in the USA or UK; the remaining
families were southern Europeans, specifically from Northern
Italy, Sicily and the Mediterranean Spanish basin. An
additional 721 MS cases, (414 and 307 from the UK and
USA, respectively), without parental HLA data were also
available for analyses of DRB1 and clinical phenotypes. A
total of 2201 (of 2294) MS cases had complete clinical and
HLA data for analysis of phenotypes (96% of the dataset);
see Table 1.
HLA-DRB1 allele associations with disease susceptibility
As expected, over-transmission of the DRB115 allele and
highly significant association between MS and DRB1 were
observed (global test in all families, P ¼ 6.7  10233;
Table 2). TheDRB115 association (P ¼ 7.8  10231) was pro-
minent in both northern and southern European datasets con-
sidered separately (data not shown). To identify predisposing
or protective effects attributable to other DRB1 alleles, the con-
founding influence of DRB115 was excluded by repeating the
analysis in just those families (n ¼ 494) without DRB115. No
significant evidence for any effects attributable to other DRB1
alleles was observed. Most notably, no evidence for any effect
of the more common DRB103 or less common DRB104
alleles associatedwithMS susceptibility in someMediterranean
(13,20,28–30), European (31) and African American popu-
lations (17) was found in this dataset. The DRB114 allele
was protective (P ¼ 0.03), although this association would not
remain significant after a conservative correction for multiple
tests. Ignoring discordant sib pairs (DSP) and only including
trios from MS families did not change results. When southern
European families were removed from the analyses, results
were very similar (data not shown).
HLA-DRB1 genotype associations with disease
susceptibility
A comprehensive strategy was employed to investigate poten-
tial DRB1 genotypic effects and MS risk. Using the genoPDT,
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we considered a total of 115 uniqueDRB1 genotypes and, in line
with the results observed for DRB1 alleles, found highly signifi-
cant evidence for associationwithMS (globalP ¼ 8.7  10217;
1294 families including 1094 triads and 1215 DSPs).
Transmissions for each individual genotype were examined,
and significant evidence for over-transmission was present
only for those genotypes carrying the DRB115 allele (data
not shown). When families carrying at least one DRB115
allele were removed from the analysis, a total of 89 unique gen-
otypes were observed. Similarly, no genotypes were associated
with MS after correction for multiple testing (494 families
including 394 triads and 338 DSPs; data not shown).
To determine whether other DRB1 alleles influence the
magnitude of risk conferred by DRB115, conditional logistic
regression (CLR) modeling of DRB1 genotypes in MS
families was then utilized. Two CLR analyses were per-
formed. First, all family members were categorized by
disease status (affected and unaffected) and DRB1 genotype.
Second, independent trios were derived from the larger
family dataset and matched ‘pseudocontrols’ were constructed
from non-transmitted parental alleles as previously described
(32). Similarly, cases from trio families and matched pseudo-
controls were categorized by DRB1 genotype for CLR model-
ing. Two reference groups were designated based on results
Table 1. Description of MS family datasets for HLA-DRB1 risk and phenotype analyses
US familiesa UK families UK MS
affected sib pairb
Spanish families Italian families
Total number
of families
527 492 204 193 127
Total number
of individuals
2534 1475 414 570 399
Total number
of MS casesc
1063 492 414 196 129
Female:male ratio 3.1:1 3.2:1 2.4:1 1.9:1 1.9:1
Mean age in
years (SD)
43.4 (10.7) 37.9 (7.3) 46.2 (11.0) 36.8 (10.4) 35. 9 (9.7)
Mean age of
onset, years (SD)
30.3 (8.7) 25.4 (6.7) 29.3 (9.2) 26.9 (8.8) 27.6 (8.3)
Mean disease duration,
years (SD)
13.1 (9.8) 12.5 (7.3) 16.9 (10.4) 7.9 (7.3) 9.8 (7.1)
RR (RR/SPMS)d n (%) 947 (89.1) 492 (100.0) 351 (84.8) 167 (85.2) 115 (90.6)
DRB115 n (%) 617 (58.0) 304 (61.8) 268 (64.7) 71 (36.2) 30 (23.3)
a307 MS cases had no available parental HLA-DRB1 data, and therefore were not used in family-based association analyses.
b414 MS cases (affected sib pairs) had no available parental HLA-DRB1 data, and therefore were not used in family-based association analyses.
cComplete clinical data was available for 2201 MS cases (of total n ¼ 2294) or 96% of the dataset.
dRRMS and SPMS together refer to a relapsing at onset disease subtype.
Table 2. P-values from PDT analyses of DRB1 in MS familiesa
Allele All families Families without DRB115
Trios T:NTb DSP A:UA P-valuec Trios T:NT DSP A:UA P-value
DRB115 698:278 439:421 7.83 10231 — — —
DRB101 163:248 78:130 3.4  1026 87:96 38:54 0.44
DRB103 265:305 149:236 0.10 131:122 60:113 0.97
DRB104 295:387 169:215 0.0069 146:148 78:90 0.86
DRB107 233:296 141:159 0.06 111:137 62:66 0.51
DRB108 68:62 41:40 0.29 33:26 10:13 0.45
DRB109 20:28 6:14 0.41 15:11 3:7 0.55
DRB110 10:13 6:5 0.59 5:5 4:3 0.78
DRB111 145:186 89:140 0.01 86:79 57:78 1.00
DRB112 27:29 12:12 0.64 13:7 2:3 0.34
DRB113 186:221 126:182 0.02 110:88 69:85 0.19
DRB114 25:62 12:44 5.7  1026 19:28 6:16 0.03
DRB116 28:38 18:13 0.69 17:24 13:9 0.49
aMS families used in PDT analyses are as follows. All (1294 families comprised of 1094 trios and 1215 DSP) and families w/o DRB115 (494 families
comprised of 394 trios and 338 DSP). The PDT v. 5.1 was used (59). Strong association overall with DRB1 was observed in the combined MS family
dataset (global test P ¼ 6.7  10233), whereas, the global test in DRB115 negative families was not significant (P ¼ 0.52).
bT, transmitted; NT, non-transmitted; A, affected; UA, unaffected.
cP-values derived from the PDT for each allele are based upon analyses of all trios and DSP when present in MS families, and are uncorrected for
multiple tests. When southern European families were removed from the analyses, results were very similar (data not shown). Very rare DRB1
alleles (,0.5% in all MS cases) are not shown in the table.
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obtained from initial genoPDT screening of DRB1 genotypes:
the ‘low-risk’ DRB1X/X (where X ¼ non-DRB115 geno-
types) and the ‘high-risk’ DRB115/15 genotype groups.
Odds ratios (OR) and 95% confidence intervals (CI) were
determined and are shown in Figure 1. Results for all family
members and cases with matched pseudocontrols using both
low (Fig. 1A) and high (Fig. 1B) risk reference DRB1 geno-
types were similar. As expected, almost all DRB115
genotypes demonstrated significantly increased odds of
disease risk when compared with the DRB1X/X genotype
reference group (Fig. 1A). The DRB115/15 genotype con-
ferred highest risk for disease (OR ¼ 9.8, 95% CI ¼ 6.6–
14.6, P , 0.0001), whereas the observed odds ratios for
DRB115/1, DRB115/3, DRB115/4, DRB115/7,
DRB115/11 and DRB115/13 genotypes ranged between
3.5 and 5.0 (P-values ,0.0001, based upon analyses of MS
cases and pseudocontrols; see Fig. 1 legend). When UK
families (n ¼ 492) were considered independently, the pre-
viously reported DRB115 dose effect on disease risk was con-
firmed (19): DRB115/15 versus DRB1X/X: OR ¼ 7.5,
95% CI ¼ 4.4–13.0, P , 0.0001 and DRB115/X versus
DRB1X/X: OR ¼ 3.4, 95% CI ¼ 2.4–4.8, P , 0.0001.
Unexpected results were observed, however, for two
DRB115 genotypes: DRB115/08 and DRB115/14.
DRB115/08 emerged as a high-risk genotype (Fig. 1A;
OR ¼ 7.7, 95% CI ¼ 4.1–14.4, P , 0.0001), and could not
be statistically distinguished from DRB115/15 (Fig. 1B;
OR ¼ 0.8, 95% CI ¼ 0.4–1.5, P ¼ 0.47). The odds for
disease was greater for carriers of DRB115/08 when compared
with DRB115/X genotypes (OR ¼ 1.9, 95% CI ¼ 1.1–3.1,
P ¼ 0.016; Table 3). Further, the DRB108 allele was more fre-
quent in DRB115/X MS cases compared with non-transmitted
parental (control) chromosomes, (5.4 versus 3.2%; P ¼ 0.02;
Table 3), which provided additional evidence for an influence
of DRB108 on MS risk, but only in the presence of DRB115.
DRB115/14 demonstrated strong evidence for a protective
effect when contrasted with DRB115/X genotypes (OR ¼ 0.2,
95% CI ¼ 0.1–0.5, P ¼ 0.0015, Table 3). In line with these
results, DRB114 was also present at a lower frequency in
DRB115/X cases when compared with non-transmitted parental
(control) chromosomes (0.2 versus 3.3%; P ¼ 0.0002; Table 3).
Considering transmission from non-DRB115 parents (present
in 350 trio families) to DRB115, positive MS cases also
revealed evidence for a protective DRB114 effect, even in the
presence of DRB115. Specifically, the rare DRB114 allele
was transmitted less often from non-DRB115 parents to
DRB115 MS cases (T:NT ¼ 1:10, P ¼ 0.01, data not shown).
Collectively, results indicate that DRB114 significantly
reduces MS risk, even for carriers of DRB115.
Similar to previous results from a Swedish MS dataset (33),
association between MS and DRB103/X genotypes was not
observed (OR ¼ 0.9, 95% CI ¼ 0.7–1.1, P ¼ 0.20);
however, when individuals carried two copies of DRB103,
evidence for a modest but increased risk for MS was present
(OR ¼ 1.8, 95% CI ¼ 1.1–2.9, P ¼ 0.03), even when
accounting for DRB115 genotypic effects (data not shown).
The DRB103/03 genotype was present in only 2.2% of MS
cases. Results indicate that CLR modeling had more power
to detect this less common genotypic effect compared with
the genoPDT.
HLA-DRB115 genotypes and clinical phenotype
The influence of HLA-DRB115 genotypes on age at onset and
disease severity was examined (total n ¼ 2201 MS cases; see
Table 1). Here, age of onset was defined as the first episode of
focal neurological dysfunction suggestive of CNS demyelinat-
ing disease (8). This information was obtained via individual
recall and verified through review of medical records. The
mean age of onset in male MS cases, overall, was very similar
to female cases (28.8+9.2 versus 28.2+8.2, respectively,
P ¼ 0.47), even when analyses were restricted to cases with
an initial RR course (P ¼ 0.70). Age of onset distributions for
MS cases grouped according to DRB115 genotype status
were compared to identify mean differences. When each
mean age of onset in cases based on DRB115 genotypic categ-
orization was compared with the mean value derived from
DRB1X/X cases, no significant differences were observed,
even after adjustment for gender and country of origin (data
not shown). Furthermore, no differences in distribution of the
DRB115 genotypes were present when male and female
cases were considered separately (data not shown).
The Global MS severity score (MSSS) was used as a
measure of disability (34). This algorithm adjusts disability
as measured by the expanded disease disability score
(EDSS) (35) for disease duration. Disease duration was
measured as the number of years between the year of onset
of first symptom and year of last exam with EDSS assessment.
The mean MSSS in male MS cases was significantly higher
when compared with female cases, even when analyses were
restricted to cases with an initial RR course (5.2+2.7 versus
4.7+2.6, P ¼ 0.0009). However, when cases were grouped
according to DRB115 genotype and compared with
DRB1X/X individuals, no statistically significant differences
in MSSS distributions were observed (Fig. 3), even after
adjustment for gender and country of origin (data not shown).
Analyses also utilized ‘mild’ and ‘severe’ designations
(most extreme clinical phenotypes) to examine, specifically,
the HLA-DRB115 dose effect as previously reported (19).
Mild disease (the ability to walk normally or have only mild
gait disability) was defined for cases with an EDSS 3 after
15 years. Severe disease (the need for bilateral assistance to
walk or wheelchair dependency) included cases who reached
an EDSS .6, within 10 years of disease duration. When
mild (n ¼ 146, 6.6% of dataset) and severe (n ¼ 97, 4.4% of
dataset) MS cases derived from the larger dataset were con-
sidered separately, the presence of DRB115 (either one or
two copies) did not distinguish one phenotype from
the other (DRB115/15 versus DRB1X/X, OR ¼ 1.8,
95% CI ¼ 0.6–5.0, P ¼ 0.29; DRB115/X versus DRB1X/
X, OR ¼ 0.8, 95% CI ¼ 0.4–1.5, P ¼ 0.54; data not shown).
HLA-DRB115 and primary progressive MS
DRB115 genotype frequencies for primary progressive MS
(PPMS) (total n ¼ 87 cases: 31 were from USA and 56 from
UK) and initial RRMS (including secondary progressive MS
(SPMS) total n ¼ 1036 cases: 544 from USA and 492 from
UK) were compared. Control DRB115 genotype frequencies
were derived using non-transmitted allele frequencies
from 433 parents of US MS cases, under assumptions of
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Figure 1. HLA-DRB115 genotype associations with disease susceptibility. OR and 95% CI from CLR analyses using low risk (A) and high risk (B) genotype
reference groups. (DRB1X/X, where X excludes DRB115 genotypes). The analyses included all affected and unaffected individuals from 1339 MS families
(total N ¼ 4669 individuals: 1571 MS cases and 3098 unaffected individuals; m:n matching) and 958 individual trio families (total N ¼ 3832: 958 MS cases
and 2874 pseudocontrols; 1:3 matching). Unaffected family members included all parents and siblings of affected individuals. Pseudocontrols were derived
from non-transmitted parental alleles (32). All analyses were performed using CLR modeling as implemented in PROC TPHREG (SAS v. 9.1; SAS Institute,
Cary, NC). All P-values for DRB1 genotype comparisons using low-risk DRB1X/X as reference group were highly significant (P, 0.0001), with the exception
of DRB114 (P. 0.25). All P-values for DRB1 genotype comparisons using high-risk DRB115/15 as reference group were significant (ranging from
P, 0.0001 to P, 0.02), with the exception of DRB108 (P . 0.30). Rare HLA-DRB1 genotypes (,1% frequency) were collapsed into the DRB115/X
(other) genotype category (DRB109, 10, 12, 1502 and 16).
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Hardy–Weinberg equilibrium (36). Similar DRB115 geno-
type frequencies were observed in both PPMS and RR/
SPMS cases and were higher compared with controls,
suggesting that DRB115 contributes to MS pathogenesis in
both subgroups (Fig. 3). These analyses were restricted to
the UK and US datasets where overall DRB115 frequencies
were similar. A total of 48 PPMS families (27 complete
trios and 38 DSPs) were also available for PDT analysis.
Figure 2. HLA-DRB115 genotypes and MSSS. MS cases were assigned a Global MSSS (34). When cases were grouped according to DRB115 genotype to test
for differences in MSSS distributions, results were very similar across the different genotypes. When resulting median or mean MSSS for each DRB1 genotype
shown here was compared with the median or mean value derived from the DRB1X/X cases, the distributions were statistically indistinguishable. The Wilcoxon
Rank Sum test and t-test (ranksum, ttest, regress in Stata v. 8.2, StataCorp LP, College Station, TX) was used to test for significant differences in MSSS
distributions (see Methods). When analyses were restricted to unrelated cases, results were very similar (data not shown).
Table 3. Summary of evidence for trans DRB1 allele interactions and risk for MS
CLR results DRB1 allele distributions derived from DRB115/X MS cases and NT parental chromosomesa
DRB1 genotype ORb 95% CI P-value DRB1 allele 15/X cases N (%) NT parental
alleles N (%)
P-value
DRB115/08 1.9 1.1–3.1 0.016 DRB108 25 (5.4) 57 (3.2) 0.02
DRB115/14 0.2 0.1–0.5 0.0015 DRB114c 1 (0.2) 59 (3.3) 0.0002
aOne case was derived from each independent trio family. Non-transmitted parental control alleles were identified using AFBAC software (36). A total
of 461 ‘X’ alleles from DRB115/X MS cases were compared with 1764 non-transmitted parental control ‘X’ alleles, where X ¼ all non-DRB115
alleles. P-values were determined using SAS (v. 9.1; SAS Institute, Cary, NC).
bOR and 95% CI from CLR analyses. DRB115/X was used as the reference group, where X ¼ all other DRB1 alleles except 08, 14 and 15. The
analyses included all affected and unaffected individuals from 1339 MS families (total N ¼ 4669 individuals: 1571 MS cases and 3098 unaffected
individuals, shown in the table) and 958 individual trio families (total N ¼ 3832: 958 MS cases and 2874 pseudocontrols); results from both compari-
sons were very similar. Unaffected family members included all parents and siblings of affected individuals. Pseudocontrols were derived from
non-transmitted parental alleles (one case per family) (32). All analyses were performed using CLR modeling as implemented in PROC TPHREG
(SAS v. 9.1; SAS Institute, Cary, NC).
cConsidering transmission from non-DRB115 parents (present in 350 trio families) to DRB115 positive MS cases also revealed evidence for a pro-
tective DRB114 effect, even in the presence of DRB115. Specifically, the rare DRB114 allele was transmitted less often from non-DRB115 parents
to DRB115 MS cases (T:NT ¼ 1:10, P ¼ 0.01 and was derived using PDT v. 5.1 (59)).
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The results were highly significant for DRB1 (global
P ¼ 0.003) and for over-transmission of DRB115, specifi-
cally (P ¼ 0.0004). PDT analyses utilized all available
PPMS families within the overall dataset.
DISCUSSION
A strong genetic association between MS and the
HLA-DRB11501, DQB10602 haplotype has been a recurrent
finding across populations, the notable exceptions being the
association with five different DRB1–DQB1 haplotypes in
cases from Sardinia (13,37), and other Mediterranean and
Asian populations (20,28,29,38). Recent studies in MS cases
from Martinique and African Americans indicate an associ-
ation with the DRB1 gene independent of DQB1 further
supporting the hypothesis that the disease is DRB1-peptide
driven (17,39). Antigenic peptides are bound to the DRB1 eno-
coded molecules in an extended conformation anchoring in
key pockets shaped by specific polymorphic residues. There
is, however, discrepancy surrounding the occurrence and
range of DRB1 allelic and genotypic heterogeneity in MS.
Here, using a large, stringently ascertained and well-
characterized familial MS dataset, a comprehensive investi-
gation of DRB1 variation and disease risk was performed.
Genetic association to HLA-DRB1 and a strong association
with DRB115 were observed in the overall dataset, as pre-
viously reported for the individual populations. The
DRB115 dose effect on susceptibility (19) was replicated,
and the preferential transmission of DRB108 in trans with
DRB115 and under-transmission of DRB114 recently
detected in MS families ascertained in Canada (21) were con-
firmed. DRB115/08 and DRB115/14 genotypes were clearly
identified as high risk and protective, respectively, for MS, in
comparison to other disease predisposing DRB115 geno-
types. These results strongly support the concept that
complex interactions among DRB1 alleles, and perhaps
extended DRB1 haplotypes and unidentified gene(s) contained
within, confer both susceptibility and resistance.
The robust DRB1 genotypic effect detected in European and
North American MS families is not consistent with a single
locus dominant disease model proposed to explain certain
HLA-disease associations, best represented by the association
of HLA-B27 and ankylosing spondylitis (40). Dominantly
acting major histocompatibility complex (MHC) genes are
thought to function via high-affinity binding to self-peptides
derived from the target organs, which are then efficiently pre-
sented to pathogenic autoreactive T cells. In MS, however,
complex DRa/DRb heterodimer effects in trans were
detected, showing a disease association gradient ranging
from high vulnerability (DRB115 homozygotes) to low sus-
ceptibility or resistance (DRB115/14 heterozygotes).
Adding to the complexity of the HLA contribution to MS, a
dose effect was also detected for DRB103 and disease risk;
however, in contrast to DRB115, the risk conferred by
DRB103 appears to be recessive, with two copies signifi-
cantly increasing risk (almost 2-fold) compared with no risk
for individuals carrying one copy, even after accounting for
DRB115. The results are similar to a recent report in
Swedish MS cases (33), but differ from a Canadian MS
study (21). MS cases from both of these populations demon-
strate a strong DRB115 association. Although a primary
DRB103 allelic association has been noted in other popu-
lations where the DRB115 effect is less prominent or
absent, this was not observed in the current study.
DRB1 alleles that confer susceptibility differ from non-
associated alleles at only a few positions in the binding site,
implying a high degree of specificity. Structural studies
demonstrate that polymorphic residues which affect the
shape and charge of the P4 pocket in the peptide-binding
site are important determinants in DRB1-associated human
autoimmune diseases. DRb11501 is different from other
DRb molecules in that aromatic residues in the ligand are pre-
ferred by the large hydrophobic P4 pocket of the peptide-
binding domain (41). For the MS putative autoantigen
myelin basic protein (MBP), this pocket is primarily occupied
by the aromatic side chain Phe92, acting as an important
primary anchor and accounting for its high-affinity binding
to the HLA-DRa0101/DRb1501 heterodimer. The poly-
morphic residue at DRb71 is critically important in creating
the necessary space for Phe92 of MBP, and the uncharged
Ala at this position is only observed for DR15 alleles
(DRB11501–DRB11506) and the rare DRB11309 allele.
Full molecular typing was available for more than 70% of
the DRB115 alleles observed in this study; .99% were
DRB11501. The two aromatic residues of the DRb1501 P4
pocket, b26Phe and b78Tyr, facilitate the binding of aromatic
side chains. The molecular structures of the permissive alleles
DRB108 and DRB10301, identified as MS-associated in this
and other studies, are significantly divergent in the proximity
of the bound peptide, suggesting either they present a different
MBP epitope or perhaps a different autoantigen. Hence, in the
case of DRB108, this allele may synergize with DRB11501
Figure 3. HLA-DRB115 genotype frequencies in MS cases grouped by
disease course. Independent cases derived from the larger family dataset
were used to characterize DRB1 genotypes in PPMS (total n ¼ 87: 31 cases
were from USA and 56 from UK) and RR/SPMS (n ¼ 1036: 544 from USA
and 492 from UK). Control genotype frequencies were derived using non-
transmitted allele frequencies from 433 parents of US MS cases, under
assumptions of Hardy–Weinberg equilibrium (36). Similar DRB115 geno-
type frequencies were observed in PPMS and RR/SPMS cases suggesting
the presence of similar DRB115-related disease mechanisms across pheno-
types. DRB115 genotype frequencies in both MS subgroups were higher
compared with controls. A total of 48 PPMS families (27 complete trios
and 38 DSPs) were also available for PDT analysis (PDT v. 5.1 (59);
results: global P-value for DRB1 ¼ 0.003; and for over-transmission of
DRB115, specifically, P ¼ 0.0004 (data not shown).
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by extending the aberrant immune response to either a minor
epitope, or a novel encrypted determinant uncovered through
molecular spreading (42).
Interestingly, alignment of all MS susceptibility alleles ident-
ified to date, DRB11501, 1503, 0301, 0401 and 0801/3 (in
this study) reveals sharing of an aromatic residue (Tyr) at pos-
ition 60, whereas the most common forms of the resistance
allele DRB114 (DRB1140101, 140102, 140103, 1404)
carry the basic residue His. DRB1 genotyping methods used
in this study did not distinguish every rare DRB114 variant;
however, .90% of alleles with high resolution typing (30%
of the dataset) were 1401 (82%) or 1404 (9%). Although
the crystal structure of DRb114 is not available, computer
modeling suggests that position 60 affects the shape and
charge of the P9 pocket at the binding site (Fig. 4). To accom-
modate the observed dominant protective effect of this allele
over DRB115, it can be speculated that sub-optimal engage-
ment of the encephalitogenic peptide leads to a dominant pro-
tective immune-deviation similar to that observed upon
injection of altered peptide ligands (APLs) (43). Despite the
apparent failure of APL in modulating MS at non-allergenic
doses, a new generation of therapeutic synthetic peptides devel-
oped based upon a better understanding of the molecular struc-
ture of HLA-DRB1 molecules and association to autoimmunity
may be available for clinical trials in the near future (44). The
observation of disparate DRB1genotypic effects on MS suscep-
tibility is consistent with a multi-locus effect model comprised
of a dominantly acting susceptibility gene present on DRB115
haplotypes (or recessive in DRB103 haplotypes) plus the
absence of a protective gene required for the maintenance of
Figure 4. Molecular modeling of HLA-DRB1 susceptibility and resistance alleles in MS. (A) Sequence alignment of various HLA-DRB1 alleles compared with
DRB11501. Arrowheads encompass the sequence of the floor of the groove that mostly interacts with the peptide (p56–p87). While all permissive alleles
exhibit a tyrosine (Y) in position 60 (boxed), the resistance allele DRB11401 displays a hystidine (H). The alignment was performed using the Immunogenetics
database (IMGT) webpage (www.ebi.ac.uk/imgt). (B) and (C) Crystallographic structure of HLA-DRb11501 bound to MBP peptide 85–98. (B) Side view of
the complex with the HLA molecule (white) in surface view and the peptide (green) in ball and stick. Allele discriminatory position b60 (Y/H) is colored in red
to highlight its proximity to the peptide, potentially altering its binding properties. Residue bA71, critical for peptide binding, is shown in yellow. The small and
uncharged bA71 creates the necessary room for the binding of large hydrophobic side antigen chain in the P4 pocket. (C) Close-up view of HLA-DRb1 position
b60 showing the Y residue (red) of allele 1501, and all possible rotamers of a modeled Y–H substitution. The OH2 terminus of the MBP peptide T97–P98 is
shown in green. In the absence of a crystal structure for b1401, all possible rotamers of a Y–H substitution were modeled using Swiss-PDB viewer (http://ca.
expasy.org/spdbv). The most thermodynamically favorable rotamers are displayed in colors, while the least favorable ones are grayed. Visualizations were
performed with the software Chimera (www.cgl.ucsf.edu/chimera).
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peripheral tolerance present on non-DRB115 haplotypes. The
proposedmodels are testable using single and double transgenic
mice exposed tomyelin epitopes (45). In addition, the imminent
availability of genetic maps defining discrete haplotype bins in
theHLA extended region (46,47) will provide a useful reference
and necessary tools to identify the true disease gene(s) for MS
operating within this superlocus.
Whether DRB115 influences age of onset or disease sever-
ity in MS has been controversial. A new measure, the MSSS,
was utilized in this study to evaluate the relationship between
expanded DRB115 genotypes and disease severity (34). The
MSSS algorithm adjusts the most validated and widely
accepted measure of disability, the EDSS (35), for disease
duration by comparing an individual’s disability with the dis-
tribution of scores in cases having equivalent disease duration.
Simulations have revealed that the MSSS may be more power-
ful than other methods for measurement of severity in MS (34)
including mild and severe categorizations and two types of
progression indices (48,49). Using the Global MSSS approach,
no significant differences in score distributions for cases
characterized by common DRB115 genotypes were detected.
Further, no evidence for a DRB115 influence on extreme
clinical phenotypes such as mild (6.6% of cases) or severe
(4.4% of cases) courses defined by EDSS and disease duration
(8,19,50) was identified. Neither age of onset nor gender in
MS cases were associated with DRB115 status or DRB115
genotypic variation (data not shown).
Common DRB115 genotypes do not appear to modulate
age of onset or severity in MS. However, ‘radiological
relapses’ using magnetic resonance imaging (MRI), defined
as the presence of gadolinium-enhancing lesions, may be a
better indicator of disease burden compared with a neurologi-
cal examination that includes the EDSS. This is currently
under debate (33), and has important implications for
genetic studies. Neither MRI nor drug therapy information
were available for all MS cases in this study. Treatment
options for MS specifically target the inflammatory phase
and include immunomodulators such as interferon betas and
glatiramer acetate, and an immunosuppressant, mitoxantrone
(51). Confounding in this study remains possible, if MS
cases with distinct DRB1 genotypes respond differentially to
particular treatments. Interestingly, DRB115 status does not
appear to influence response to interferon therapy (27),
though larger studies are needed to fully address this question.
MS cases with a primary progressive disease course
(PPMS), ~10% of all cases, experience a gradual but insidious
progression of disability from onset without superimposed
relapses, and demonstrate additional demographic, pathologi-
cal and imaging features which distinguish them from
RRMS (52–54). It is not certain if these features result
from different aetiologic mechanisms or, alternatively,
represent opposite ends of a clinical spectrum. Whether
HLA-DRB115 is associated with PPMS, specifically, has
not been previously established; several small studies failed
to show any association between PPMS and DRB115,
whereas others appeared to show association (25,48,55). In
this study, DRB115 status did not distinguish PPMS from
RR/SPMS, as DRB115 frequencies were very similar in
both subgroups. In addition, PPMS families also demonstrated
significant evidence for over-transmission of DRB115 to MS
cases. Taken together, these results suggest PPMS and
RR/SPMS share a common HLA-related pathoaetiology, and
indicate both phenotypes are within the same disease spec-
trum. If correct, this model has important implications for
disease pathogenesis and therapy.
In summary, our results show that the DRB1 contribution to
MS risk is more complex than originally considered. Whether
genotypic heterogeneity in MS is due to differences in affinity
attributed to specific DRB1 alleles for a number of auto-
antigenic peptides, or indicates the involvement of other
nearby genes within the MHC remains unknown. In light of
these findings, functional studies of MS-related DRB1 alleles
and genotypic combinations identified in this study are
warranted.
MATERIALS AND METHODS
Diagnostic criteria, ascertainment protocols and clinical and
demographic characteristics for MS cases and family
members are summarized elsewhere (19,20,27,56). Appropri-
ate institutional review boards approved all studies and written
informed consent was obtained from all participants.
HLA-DRB1 genotypes were determined as previously
described (19,57); both low (two digit) and medium (four
digit) resolution typing methods were utilized. Medium resol-
ution typing was available for approximately half of the entire
dataset, or 50.3% of all alleles; the majority of these were
DRB115. More than 70% of the DRB115 alleles observed
in this study had four digit typing; .99% were characterized
as DRB11501. DRB1 genotyping methods used in this study
did not distinguish every rare DRB114 variant; however,
.90% of alleles with medium resolution typing (30% of the
dataset) were 1401 (82%) or 1404 (9%). Medium resolution
typing was performed for 50% of DRB103 alleles (99% were
distinguished as 0301) and 32% of DRB108 alleles (78%
were 0801 and 16% were 0803). To maximize the statistical
power of the large MS family dataset, low resolution allele
grouping was used for all analyses.
All family genotypes were examined for Mendelian incon-
sistencies using PEDCHECK (58) and any discrepancies
addressed. Family-based association analyses using the pedi-
gree disequilibrium test (PDT) v. 5.1 (59) were performed.
Two PDT statistics were used: the PDT-sum statistic (60),
which examines allelic effects, and the genotype-PDT that
examines genotypic effects (61). The PDT is a powerful
analytical method that uses genetic data from related nuclear
families and discordant sibships within extended pedigrees.
CLR modeling of DRB1 genotypes in MS families was used
to assess the magnitude of disease risk associated with
DRB115 and DRB103 genotypes in the MS families using
PROC THREG as implemented in SAS (v. 9.1; SAS Institute,
Cary, NC). All affected and unaffected family members were
utilized in this analysis with m:n matching (where a varying
number of affected and unaffected members were present in
each matched set or family). In addition, one MS case and
three matched ‘pseudocontrols’ constructed from the non-
transmitted parental alleles, as previously described (32),
were used in (CLR) analyses. One fully genotyped indepen-
dent trio (both parents and one affected) from each MS
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family was selected for this analysis. Affected family-based
controls (AFBAC) (non-transmitted parental alleles or
‘AFBAC’) were derived as previously described (36). The
x2 test of heterogeneity was used to test the null hypothesis
that the distribution of non-DRB115 or ‘X’ alleles in
DRB115/X MS cases is similar to the distribution of
non-DRB115 or ‘X’ alleles in controls. P-values, OR and
CI for all x2 or Fisher’s exact test of allele or genotype
case–control comparisons were derived using SAS (v. 9.1;
SAS Institute, Cary, NC).
The MSSS (34) was used to examine DRB1 genotypic
effects influencing severity. The MSSS algorithm is a simple
method for adjusting disability for disease duration, and is
based upon data obtained from a collection of ~10 000 MS
cases across the world. The Global MSSS is the decile of
the EDSS within the range of cases who have had the
disease for the same duration. Cases in this study were
assigned a global score and then tested for differences in
median scores between cases grouped according to DRB1 gen-
otypic categories using the non-parametric Wilcoxon Rank
Sum test implemented in ranksum (Stata v. 8.2, StataCorp
LP, College Station, TX). Two sample t-tests and linear
regression were also used to compare mean MSSS in cases
grouped according to DRB1 genotype. These analyses were
performed in Stata (regress, ttest, Stata v. 8.2), and results
were adjusted for gender and country of origin. Cases for
whom EDSS scores were designated as ,3 or 3–5.5 were
assigned an average score (total n ¼ 738 cases) based on the
Global MSSS assigned for disease duration at both ends of
the range. Results obtained from analyses including and
excluding these individuals were identical (data not shown).
Similarly, two sample t-tests and linear regression were used
to compare age of onset distributions in cases grouped accord-
ing to DRB1 genotype, as described above; results were
adjusted for gender and country of origin. Age of onset and
MSSS analyses using the entire dataset (n ¼ 2201) or
restricted to unrelated MS cases only (n ¼ 1743) were very
similar. Results obtained from unrelated MS cases are reported
in the text.
EDSS scores were used in conjunction with disease duration
to define mild or severe forms of MS. Disease duration was
measured as the number of years between the year of onset
of first symptom and year of last exam with EDSS assessment;
in most cases, this is at entry of study, given the cross-
sectional nature of these datasets. Mild disease (the ability
to walk normally or have only mild gait disability) was
defined as those cases with an EDSS 3 after 15 years.
Severe disease (need for bilateral assistance to walk or wheel-
chair dependency), included cases who reached an EDSS .6,
within 10 years of disease duration. Logistic regression
models were used to determine the odds of DRB115 carrier
status (copy number) in mild versus severe MS case groups
using PROC GENMOD (SAS v. 9.1; SAS Institute, Cary,
NC). All odds ratios were adjusted for gender.
Sequence alignment and comparison of predisposing and
protective HLA-DRB1 alleles to DRB11501 was performed
using the Immunogenetics database (IMGT) webpage (www.
ebi.ac.uk/imgt). Visualizations for HLA-DRB1 alleles
were performed with the Chimera software (www.cgl.ucsf.
edu/chimera).
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